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Clinical ResearchCarotid Angioplasty With Stenting
Versus Endarterectomy
10-Year Randomized Trial in a Community Hospital
William H. Brooks, MD,* Michael R. Jones, MD,* Paula Gisler, PHD,*
Rick R. McClure, MD,y Timothy C. Coleman, MD,* Linda Breathitt, RN,*
Cheryl Spear, RN*
Lexington, KentuckyObjectives This single-center, randomized, clinical trial was designed to determine the 10-year
comparative efﬁcacy and durability of carotid angioplasty and stenting (CAS) versus carotid
endarterectomy (CEA) in preventing ipsilateral ischemic stroke in symptomatic and asymptomatic
patients with high-grade carotid artery stenosis.
Background Modern clinical trials with short-term follow-up indicate CAS and CEA are equivalent in
reducing the risk for ipsilateral ischemic stroke secondary to carotid stenosis. A paucity of data exists
regarding long-term outcomes.
Methods Patients of all surgical risks with symptomatic and asymptomatic carotid stenosis (>70%)
were randomly selected for CEA or CAS and followed a minimum of 10 years.
Results Long-term follow-up was achieved in 173 patients (91%). Eighty-seven (50.2%) died within
this period, most commonly of nonvascular causes. No difference in the risk of stroke ipsilateral to the
treated artery was noted among treatment groups (p > 0.05). Restenosis determined by sequential
ultrasound was assessed only in the CAS group (3.3%) and remained asymptomatic. The combined risk
of fatal or nonfatal heart attack over the 10-year period was highest in individuals with symptomatic
versus asymptomatic stenosis (27.5% vs. 11.0%; hazard ratio [HR]: 2.32, 95% conﬁdence interval [CI]:
1.298 to 4.146, p ¼ 0.005) and was higher in all patients treated with CEA (HR: 2.27, 95% CI: 1.35 to
3.816, p ¼ 0.002).
Conclusions Long-term protection against ipsilateral stroke provided by CAS and CEA did not differ in
this trial. The 10-year risk of fatal/nonfatal myocardial infarction was highest in all patients harboring
symptomatic carotid stenosis at enrollment. The risk of fatal/nonfatal heart attack was signiﬁcantly
more prevalent in those symptomatic or asymptomatic patients randomized to CEA. (J Am Coll
Cardiol Intv 2014;7:163–8) ª 2014 by the American College of Cardiology FoundationFrom the *Baptist Health Lexington, Lexington, Kentucky; and the yDepartment of Cardiology, University of Kentucky,
Lexington, Kentucky. All authors have reported that they have no relationships relevant to the contents of this paper to disclose.
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164The durability of carotid endarterectomy (CEA) for revas-
cularization of high-grade carotid stenosis as deﬁned by
protection against ipsilateral stroke and absence of restenosis
is well established through a series of randomized, controlled
trials (1–5). The ECST (European Carotid Study Trial)See page 169observed the 10-year risk of stroke after CEA was approx-
imately 2% per year. Less than one-half of these were related
to residual or recurrent disease in the treated artery (5). The
Mayo Clinic reported the restenosis rate following successful
CEA was 0.1%, with no strokes at an average of 7 years of
follow-up (6). Although CEA has long been considered the
preferred intervention for carotid occlusive disease, recent
randomized clinical trials (RCT) have indicated that carotid
angioplasty and stenting (CAS) may serve as a minimally
invasive alternative with equivalency in providing protection
against ipsilateral stroke (7–11). Whereas these studies have
reported favorable short- and mid-term (3 to 5 year) results,Abbreviations
and Acronyms
CAS = carotid angioplasty
and stenting
CEA = carotid
endarterectomy
CI = conﬁdence interval(s)
DUS = duplex ultrasound
HR = hazard ratio(s)
RCT = randomized clinical
trial(s)longer-term data, similar to that
available for CEA, are lacking.
Thus, despite the satisfactory
early results, concern remains
about the long-term durability of
CAS.
The initial results of the
Kentucky trial were presented
over a decade ago (7,8). In this
prospective, randomized trial,
patients of all surgical risk cate-
gories with symptomatic or
asymptomatic carotid artery ste-nosis were offered randomization into CEA versus CAS
treatment groups. The results indicated that a clinical
equipoise exists between the 2 revascularization strategies at
30 days and at 48 months. Extending our initial ﬁndings,
the current report compares the long-term (10 years)
durability and consequences of CAS with CEA in this
randomized cohort of symptomatic and asymptomatic in-
dividuals with carotid artery stenosis.
Methods
The inclusion and exclusion criteria, methodology, and
initial results of the Kentucky RCT comparing CEA with
stenting have been published (7,8). Brieﬂy, all patients
presenting with symptomatic or asymptomatic carotid ste-
nosis from 1998 through 2002 meeting the inclusion or
exclusion criteria were offered enrollment. No anatomic risk
factors or concurrent medical conditions other than those
contained in the exclusionary criteria were considered
in treatment assignment (7,8). Embolic protection devices
were not available at the initiation of this trial and thus werenot used. These RCT were approved by the institutional
review board. A neurologist (T.C.C.) and research nurse
coordinators (L.B., C.S.) provided independent oversight
and neurological examination at speciﬁc prescribed intervals.
Sequential independent neurological examinations and
Rankin and Barthel scorings were performed concurrent
with duplex scanning. This RCT was designed speciﬁcally
to assess the initial (30 days), intermediate (48 months), and
long-term (10 years) safety and efﬁcacy of CAS and CEA
in a community hospital.
The presence of extracranial atherosclerosis was estab-
lished by a combination of duplex ultrasound (DUS) and
cerebral angiography (7,8). Carotid DUS was assessed
within 24 h of the index procedure and at 1, 3, 6, 12,
and 24 months and thereafter at 12-month intervals for
10 years. The protocol for DUS included B-mode and
angle-adjusted Doppler spectral imaging as standardized in
the core ultrasound laboratory at Central Baptist Hospital,
consistent with guidelines of the CREST (Carotid Revas-
cularization Endarterectomy versus Stenting Trial) (9). Data
were obtained from the treated and untreated carotid artery.
Throughout this study, DUS accuracy and uniformity was
conﬁrmed by correlation with carotid angiography per-
formed in individuals admitted to the stroke service but
not enrolled in this RCT. Recurrent stenosis (>70%)
was determined and deﬁned as development of internal
carotid artery peak velocities >300 cm/s and internal carotid
artery/common carotid artery ratio of >3 subsequent to and
compared with a previous ultrasound examination that
showed no evidence of stenosis. All cases suspected of
restenosis were conﬁrmed by cerebral angiography.
A standardized pre-randomization assessment of risk fac-
tors and a post-procedural medical protocol were prescribed
for all patients that included maintenance of systolic blood
pressure at or below 140 mm Hg as recorded during each
ofﬁce visit; platelet inhibition with 325 mg of aspirin plus 75
mg of clopidogrel; encouragement for cessation of smoking,
and prescribing statin therapy regardless of serum cholesterol
levels. No speciﬁc pharmacological protocol for mana-
ging blood pressure was mandated. Post-procedural protocol
compliance was based on patient and family self-report.
Adverse clinical events were deﬁned as any stroke of any
severity regardless of location, symptomatic ischemic heart
disease, and/or death from any cause. The cause of death or
morbidity was conﬁrmed through family contact and review
of medical records.
Statistical analysis. Kaplan-Meier survival curves were
generated for all asymptomatic and symptomatic CAS and
CEA groups as well as for combined CAS and CEA
asymptomatic and symptomatic cohorts. For each subject,
person-time days at risk were calculated for all strokes,
ipsilateral stroke, all myocardial infarctions, and all com-
bined vascular adverse events. Each of these variables
included both fatal and nonfatal events. Values were
Table 1. Mortality and Morbidity From Stroke
Deaths from stroke
CEA (n ¼ 1):
6 years from index procedure: hemorrhagic, contralateral
CAS (n ¼ 5):
1. 7 years from index procedure: ischemic; ipsilateral
2. 8 years from the index procedure: ischemic; vertebral basilar
3. 9 years from index procedure: hemorrhagic; contralateral
4. 9 years from index procedure: ischemic; vertebral basilar
5. 10 years from index procedure: ischemic; contralateral
Nonfatal strokes
CEA: 0 of 83
CAS: 4 of 90
CAS ¼ carotid angioplasty and stenting; CEA ¼ carotid endarterectomy.
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165censored if patients were known to have survived beyond the
period of observation in the trial. No values were censored
because of patients lost to follow-up or unknown outcomes.
Differences in Kaplan-Meier survival curves were analyzed
for signiﬁcance using the log-rank test (p < 0.05).
The impact of risk factors for each adverse event group
was analyzed using Cox proportional hazards analysis with
the proportionality of survival curves visually assessed.
Hazard ratios (HR) were evaluated for signiﬁcance based on
p values of <0.05 as well as 95% conﬁdence intervals (CI).
Before all analyses, all groups were assessed for differences
using chi-square test for independence for categorical
variables, including treatment of hypertension, smoking, use
of statins, and platelet inhibition and presence of coronary
vascular disease. Cramer V values were used to test differ-
ences between procedure and symptom status groups.
Pearson chi-square with continuity correction was used to
test for differences between the CEA and CAS groups.
One-way between-groups analysis of variance with Tukey
post hoc test was used to test for signiﬁcant differences in
the continuous variable of age. SPSS statistical software
(version 19.0, SPSS, Inc., IBM, Armonk, New York) was
used to evaluate the data (12).
Results
Among the 189 patients initially enrolled in the Kentucky
trials, 53 symptomatic patients and 41 individuals with
asymptomatic carotid stenosis were assigned to endarterec-
tomy and 51 patients with symptomatic stenosis and
44 asymptomatic individuals were treated by CAS (7,8).
Within the initial reporting period, 1 symptomatic patient in
the CEA group died from an immediate post-operative
myocardial infarction. One patient randomized to CAS
experienced transient cerebral ischemia (National Institutes
of Health Stroke Scale <4) during the procedure, which
resolved within 30 min. Sixteen patients withdrew. The
remaining 173 (91%) patients were monitored sequentially
for a minimum of 10 years (range 10 to 13 years). All groups
with symptomatic and asymptomatic carotid stenoses were
similar in age, ischemic heart disease, tobacco abuse, and use
of statin and antiplatelet therapy (p > 0.05).
Within the follow-up period, 87 (50.2%) initially enrolled
patients died; the majority (47 of 87; 54%) of which resulted
from nonvascular conditions, such as malignancy or pul-
monary disease. Death related to all strokes was uncommon
(6 of 173; 3.5%) but slightly more prevalent in the CAS
group (5 of 90; 5.7%) than those undergoing CEA (1 of 83;
1.1%) However, only 1 of these, occurring 7 years after the
indexed procedure, was ischemic and ipsilateral to the
treated artery. All others (4) were hemorrhagic, contralateral
to the treated artery, or vertebral-basilar in distribution, and
hence, unrelated to the procedure (Table 1). Furthermore,
although nonfatal ischemic strokes were observed only inthose assigned to CAS, none occurred in the distribution of
the indexed carotid artery.
Ischemic cardiac disease was implicated in 39% (34 of 87)
of all observed deaths. The occurrence of fatal and nonfatal
ischemic heart disease was more commonly associated with
CEA (HR: 2.27; 95% CI: 1.35 to 3.815; p ¼ 0.002) (Fig. 1)
and those enrolled with symptomatic stenosis when com-
pared with asymptomatic individuals (HR: 2.32; 95% CI:
1.298 to 4.146; p ¼ 0.005) (Fig. 2). Both asymptomatic and
symptomatic groups randomized to CAS fared far better for
all myocardial events than those undergoing CEA in the
context of time from the periprocedural period throughout
the 10-year follow-up (p ¼ 0.001) (Fig. 3).
Restenosis as deﬁned by the DUS criteria of an internal
carotid artery/common carotid artery ratio >3.0 and peak
systolic velocity of >300 m/sec was remarkably infrequent
(data not shown). Those that did occur (n ¼ 3) were
conﬁrmed by angiography at 5, 8, and 9 years after inter-
vention and were successfully treated with angioplasty
without complication. All lesions were smooth without ul-
ceration and asymptomatic. No stenosis of >80% was
observed in the CEA group. No stenosis >70% as deﬁned
by DUS was noted to occur in the contralateral untreated
artery of any group (data not shown).
In addition to sequential neurological examination and
serial DUS determinations, protocols were designed to
identify and modify risk factors associated with vascular
disease. Age, at time of enrollment, was found not to be a risk
factor for any adverse outcome (p ¼ 0.07). The presence of
hypertension (HR: 3.872; 95% CI: 1.196 to 12.537; p ¼
0.02) and cardiovascular disease (HR: 10.014; 95% CI:
2.435 to 41.178; p ¼ 0.001) at time of enrollment were
signiﬁcant risk factors for all adverse advents in all groups.
The attempt to aggressively modify these factors and use of
statin therapy did not lessen the occurrence of restenosis or
adverse events of any group (p > 0.05).
Overall, the combined risk for and incidence of stroke
ipsilateral to the treated artery and myocardial infarction
was most common in symptomatic patients randomized
Figure 1. Kaplan-Meier Curves for Fatal and Nonfatal Myocardial Infarction
in CEA and CAS Cohorts
Log rank p ¼ 0.028. CASall ¼ carotid artery stenting patients symptomatic and
asymptomatic combined; CEAall ¼ carotid endarterectomy patients symptom-
atic and asymptomatic combined; Cum¼ cumulative;MI¼myocardial infarction.
Figure 2. Kaplan-Meier Curves for Fatal and Nonfatal MI in Asymptomatic
and Symptomatic CEA and CAS Cohorts
Log rank p ¼ 0.001. Asymptomatic CAS and CEA ¼ combined asymptomatic
patients receiving carotid artery stenting or endarterectomy; symptomatic
CAS and CEA ¼ combined symptomatic patients receiving carotid artery
stenting or endarterectomy; other abbreviations as in Figure 1.
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166to CEA (HR: 5.702; 95% CI: 2.293 to 14.18; p ¼ 0.001)
followed by symptomatic individuals treated by CAS
(HR: 3.996, 95% CI: 1.58 to 10.102, p ¼ 0.003) (Fig. 4).
The risk and incidence of similar events was markedly less
in asymptomatic individuals, yet still more prevalent in
those randomized to CEA (HR: 2.27; 95% CI: 1.35 to
3.816; p ¼ 0.002).Discussion
Although RCT indicate that the early and intermediate-
term safety and effectiveness of CAS is similar to CEA in
restoring carotid artery patency and stroke prevention, the
critical issues of long-term durability and efﬁcacy of carotid
artery stenting in the context of ipsilateral stroke prevention,
patency, and consequences remain largely unknown. This
trial provides the ﬁrst long-term evidence that CAS and
CEA are not only equally effective, but also durable in
ipsilateral stroke prevention in individuals harboring high-
grade stenoses (>70%). Overall, no signiﬁcant differences
were identiﬁed in the occurrence of ipsilateral stroke be-
tween those randomized to CEA or CAS (p > 0.05). Age,
smoking, and statin use did not lessen the risk for an adverse
events in any cohort. However, the risks and clinical out-
comes in the context of both fatal/nonfatal stroke and
ischemic heart disease are strongly associated with the
presence of symptomatic carotid stenosis at the time ofenrollment and intervention. Accordingly, individuals un-
dergoing intervention for asymptomatic stenosis carry
signiﬁcantly less risk for late cerebral and/or cardiac adverse
events when compared with those presenting with symp-
toms of carotid stenosis. Furthermore, the risk for the
occurrence of any adverse event was less in those individuals
randomized to CAS than in those treated by CEA (HR:
1.649, 95% CI: 1.025 to 2.653, p ¼ 0.039).
Shorter-term trials comparing stenting with endarterec-
tomy have shown that troponin and/or other cardiac
biomarker release, consistent with procedurally related
myocardial injury, is more common during endarterectomy
thanwith stenting (9,13). Although largely asymptomatic and
unassociated with diagnostic electrocardiographic changes,
these markers have been shown to be a negative prognostic
indicator in terms of increased risk for subsequent ischemic
heart disease (14,15). Although cardiac biomarkers were not
assessed in this trial, both asymptomatic and symptomatic
groups randomized to CAS fared better than their cohort
undergoing CEA in the context of lessened incidence and risk
for myocardial infarction, thereby suggesting that cardiac
biomarker “leak” associated withCEAmay indeed carry long-
term clinical signiﬁcance. Indeed, the increased risk for
myocardial ischemia subsequent to CEA extended
throughout the 10 years of this trial. The increased risk for
myocardial infarction in symptomatic versus asymptomatic
patients is poorly understood, but it is likely consistent with
Figure 4. Kaplan-Meier Curves for Ipsilateral Stroke and Fatal and Nonfatal
MI for CEA Asymptomatic, CEA Symptomatic, CAS Asymptomatic,
and CAS Symptomatic Cohorts
Log rank p ¼ 0.001. Abbreviations as in Figures 1 and 3.
Figure 3. Kaplan-Meier Curves for Fatal and Nonfatal MI in CEA
Asymptomatic, CEA Symptomatic, CAS Asymptomatic, and CAS
Symptomatic Cohorts
Log rank p ¼ 0.001. CASasymp ¼ carotid artery stenting asymptomatic cohort;
CASsymp ¼ carotid artery stenting symptomatic cohort; CEAasymp ¼ carotid
endarterectomy asymptomatic cohort; CEAsymp ¼ carotid endarterectomy
symptomatic cohort; other abbreviations as in Figure 1.
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167the concept that atherosclerosis may be present as a general-
ized, inﬂammatory disorder (16,17).
Whereas CEA has been associated with an increased risk
for subsequent cardiac ischemia, CAS is correlated with
an increased risk of procedurally related strokes (9,10) and
an increased number of ischemic alterations in the brain
demonstrated by magnetic resonance imaging (18). No
differences between the procedures in the risk and/or inci-
dence of ipsilateral stroke were found in this composite trial.
Nevertheless, the overall occurrence of any cerebrovascular
event was more prevalent in the CAS group. The link
between late hemorrhagic and vertebral-basilar stroke and
CAS was not attributable to enrollment risk factors or
speciﬁc anatomic factors noted at the time or subsequent to
the procedure and, thus, remains problematic. The initial
report of this trial indicated that no differences in the
generation of ischemic changes were observed on ﬂuid-
attenuated inversion recovery sequence magnetic resonance
imaging of individuals in either group (7). However, the
relevance and importance of an increase in asymptomatic
ischemic changes in the brain subsequent to CAS in other
studies using more sensitive diffusion-weighted magnetic
resonance imaging should not be dismissed (19). Despite
initial observations that these alterations may be asymptom-
atic, the long-term sequelae of silent ischemia of the brain are
not known.Thus, whereas this RCThas shown the long-termefﬁcacies of CAS and CEA in preventing ipsilateral stoke are
similar, the even longer-term, more subtle consequences of
these procedures on brain function or manifestations of
ischemic heart disease, respectively, remain problematic.
These collective observations are particularly cogent when
considering intervention for individuals who harbor asymp-
tomatic carotid stenosis, given the results of contemporary
medical management of occlusive vascular disease and where
the risk of ipsilateral cerebral ischemic events are predicted to
occur with a very low frequency (20,21).
Prevention of ipsilateral stroke is the ultimate goal of any
treatment for critical carotid stenosis. However, durability,
deﬁned as patency determined by DUS, may also serve to
deﬁne therapeutic utility. Accordingly, it is inferred that
progressive stenosis carries increased risk for ipsilateral
stroke. Durability associated with CEA is well documented,
although the direct association of restenosis and incipient
stroke remains unknown. Restenosis of the carotid artery
following CEA ranges from 8.8% to up to 19%, yet only
0.6% to 3.6% of these become symptomatic (22,23). Indeed,
it is suggested that long-term surveillance of CEA using
DUS is unnecessary (24). In view of our observation that the
risk of restenosis is very small and remained asymptomatic,
occurring at a rate of 0.3% per year, sequential DUS also
may not be necessary for CAS. This ﬁnding is consistent
with shorter studies of CAS in which a low frequency of in-
stent stenosis is reported, and all individuals remained
asymptomatic (25–28).
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168Study limitations. The small sample sizedparticularly with
regard to the incidence of fatal and nonfatal strokedis
a limitation. Though the data for stroke were statistically
analyzed and showed no difference across procedure,
symptom status, or modiﬁcation of risk factors, the single-
digit stroke sample size impairs the validity of the statistical
analysis. However, this does not detract from the overall
implications supported by ipsilateral stroke data. Finally,
because the study was conﬁned to 1 center where the same
small number of highly experienced physicians performed all
aspects of the protocol, this study lacks the skill variability
seen in multicenter studies that marks more-typical practice.
Thus, this may limit this study’s external validity.
The strengths of the study are that there was remarkably
little patient attrition (91%) over the 10 years. Similarly, the
same physicians and research coordinator were present
throughout the 10-year study, enhancing data reliability and
integrity. Finally, this is the ﬁrst RCT designed to compare
the long-term (10-year) efﬁcacy and durability of carotid
stenting and endarterectomy.Conclusions
The collective data from this long-term trial clearly suggest
that CAS and CEA are equally effective in long-term pre-
vention of ipsilateral ischemic stroke. Furthermore, these
observations suggest CAS may be superior in the context of
overall, long-term event-free survival.
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